CCX140: Additional Phase II data

Additional data from a 52-week, double-blind, European Phase II trial in 196 evaluable patients with diabetic nephropathy showed once-daily 5 mg oral CCX140 plus standard

Read the full 250 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE